期刊
JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY
卷 14, 期 9, 页码 S40-S47出版社
WILEY
DOI: 10.1046/j.1540-8167.14.s9.20.x
关键词
atrial fibrillation; antiarrhythmic drug; electrical remodeling; ion channels
Advances in Drug Therapy for AF. Despite the major new insights into our knowledge of the mechanisms underlying initiation and perpetuation of atrial fibrillation (AF) gained in the last decade, the treatment of this common arrhythmia remains unsatisfactory in many patients. Although several new treatment modalities (e.g., internal cardioversion, pulmonary vein ablation, preventive pacing) have been developed, pharmacologic therapy remains the first-line therapy in most patients with AF. As illustrated by recent trials comparing rhythm control and rate control, current antifibrillatory drugs are hampered by a relatively low success rate in maintaining long-term sinus rhythm and the occurrence of proarrhythmic and other adverse events. This article discusses currently available antiarrhythmic drugs for rhythm and rate control, with special emphasis on more recently developed drugs and drugs still under development. Selective blockers of atrial ion channels (I-Kur and I-K.ACh), multi-ion channel blockers, and selective A(1)-adenosine receptor antagonists are examples of the newer antiarrhythmic drugs that are expected to be more effective and safer than those currently available.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据